Accumulation Phosphatidic Acid Increases Vancomycin Resistance Escherichia coli
Holly  Sutterlin Sisi Zhang,b Thomas J. Silhavya
Department Molecular Biology, Princeton University, Princeton, New Jersey, USAa; Lewis-Sigler Institute Integrative Genomics, Princeton University, Princeton, New
Jersey, USAb
 Gram-negative bacteria, lipopolysaccharide (LPS) contributes robust permeability barrier outer membrane, pre-
venting entry toxic molecules antibiotics. Mutations lptD, beta-barrel component LPS transport 
sembly machinery, compromise LPS assembly result increased antibiotic sensitivity.  report rare vancomycin-
resistant suppressors improve barrier function subset lptD mutations. seven suppressors analyzed
mapped essential gene cdsA, responsible conversion phosphatidic acid CDP-diacylglycerol phos-
pholipid biosynthesis. cdsA mutations cause partial loss function  expected, accumulate phosphatidic acid. suppression confined mutations cause defects outer membrane biogenesis cdsA mutations confer general increase vancomycin resistance, wild-type cell. use genetics quadrupole time flight (Q-TOF) liquid chromatography-mass spectrometry (LC-MS) accumulation phosphatidic acid means cdsA mutations increases resistance vancomycin. suggest increased levels phosphatidic acid change physical properties outer membrane impede entry vancomycin periplasm, hindering access target, intermediate required synthesis peptidoglycan cell wall.



T   outer membrane (OM) Gram-negative bacteria serves     robust permeability barrier (1). Composed lipopolysac-
charide (LPS) molecules outer leaflet glycerophospho-
                                                                                       CDP-diacylglycerol step commitment                                                                                        zwitterionic GPL pathway acidic GPL pathway (6, 12).
                                                                                           work, focus E. coli mutants defective LPS 
lipids (GPLs) inner leaflet, OM protects cell                      sembly exhibit increased sensitivity antibiotics. Mutations
harmful agents, detergents antibiotics (1â€“3). LPS                       compromise function LptD, beta-barrel compo-
synthesized inner membrane (IM), transported                         nent Lpt machinery, sensitive vancomycin. aqueous periplasm, finally assembled outer leaflet                     order act cell wall target, vancomycin traverse OM (4). Lpt proteins responsible transport                        OM. periplasm, vancomycin binds termi- assembly (5). Glycerophospholipids (GPLs) synthesized                          nal D-alanine residues cell wall precursor lipid II, pre- IM, little known transport                        venting polymerization peptidoglycan cell wall (13, 14).
periplasm assembly OM (6). coordination LPS                        lptD mutants exhibit increased sensitivity vancomycin GPL assembly important maintain effective OM                          allow efficient entry drug periplasm
meability barrier (1).
                                                                                       result compromised OM barrier.
    high density LPS outer leaflet, OM
                                                                                           report isolation characterization vancomy-
carries net negative charge (7). human innate immune sys-
                                                                                       cin-resistant suppressors subset lptD mutations. sup-
tem takes advantage property OM producing
                                                                                       pressors map essential gene cdsA. Vancomycin-resistant
cationic antimicrobial peptides (CAMPs) (8). Positively charged
CAMPs associate negatively charged cell surface                        suppression specific lptD mutants; cdsA mutations
sert OM, killing bacterial cell (8). Bacteria sys-                   actually increase vancomycin resistance wild-
tems place, PhoPQ virulence Salmonella                        type cell. cdsA mutations cause recessive, partial loss enterica serovar Typhimurium, modify lipid PL                           function, accumulate PA like cdsA mutants previ-
content decrease negative charge OM,                          ously described (15, 16). suggest increased PA alters creasing affinity CAMPs OM (9â€“11). increases                       OM causes increased resistance vancomycin.
bacterial resistance CAMPs enables evasion immune 
    Like LPS, GPLs contribute electric charge membrane. Escherichia coli membranes composed major GPLs: phosphatidylethanolamine (PE), phosphatidylglyc-                              Received 20 2014 Accepted 16 June 2014
erol (PG), cardiolipin (CL). relative abundances                          Published ahead print 23 June 2014 GPL species similar IM OM (PE, 75 ; PG,                           Address correspondence Thomas J. Silhavy, tsilhavy@exchange.Princeton.EDU.
20 ; CL, 5 ) (12). PE zwitterionic GPL neutral charge,                        Supplemental material article http://dx.doi.org/10.1128 PG CL acidic GPLs carry negative charges (6).                          /JB.01876-14. GPLs different chemical properties                             Copyright Â© 2014, American Society Microbiology. Rights Reserved. head groups, synthesized precursor                           doi:10.1128/JB.01876-14
molecule, phosphatidic acid (PA) (6, 12). conversion PA 

3214   jb.asm.org                                   Journal Bacteriology   p. 3214 â€“3220                                     September 2014 Volume 196 Number 18
                                                                                                          Phosphatidic Acid Increases Vancomycin Resistance



TABLE 1 Strains plasmids used study                               romycin, 30 â?®g moxalactam, 0.1 â?®g norfloxacin, 260 â?®g paraquat, 300
Strain                                                  Reference          units polymyxin B, 1 mg vancomycin. Isopropyl-â?¤-D-1-thiogalactopy-
plasmid            Relevant features                       source      ranoside (IPTG; 0.1 mM) present LB agar indicated.
                                                                                  Growth rate determination. Overnight cultures diluted 1:100 Strains                                                                       100 â?®l LB medium 96 plates. microliters min-
   MC4100          Fâ«º araD139 âŒ¬(argF-lac)U169 rpsL150      17                 eral oil overlaid prevent evaporation. Optical density 600 nm
                     relA1 flbB5301 deoC1 ptsF25 rbsR                         (OD600) measured 20 min intermittent orbital shaking                      thi                                                      37Â°C. 4-hour OD600 growth curves used determine   NR754            MC4100 Araâ«¹                             18                 growth rate. OD600 plotted time logarithmic scale,   HC334            NR754 âŒ¬lptD pET2342::lptDI54E           21, 48, 49;   linear regression analysis used determine growth rate                                                               study           culture. strain, technical replicates biological rep-
  HC338            NR754 âŒ¬lptD pET2342::lptDV52E-I54E      21, 48, 49;   licates averaged mean averages calculated                                                               study           reported standard error mean.
  HC340            NR754 âŒ¬lptD pET2342::lptD               21, 48, 49;       Cell size measurements. Overnight cultures diluted 1:100                                                               study           grown OD600 approximately 0.4. Cells suspended 1 
  HC342            NR754 cdsA7 dgt::Tn10                   study         agarose pad imaged using 100â«» 1.4-numerical-aperture (NA) ob-
  HC351            HC334 âŒ¬clsA::kan                        34; study     jective Nikon 90i microscope equipped QImaging Rolera XR
  HC386            HC334 cdsA7 dgt::Tn10                   study         camera NIS Elements software. Cell dimensions quantified   HC509            NR754 âŒ¬lptD pET2342::lptDâŒ¬D57âŒ¬K60       21, 48, 49;   MicrobeTracker version 0.936 (22), using MATLAB version R2013a. Ap-
                                                              study           proximately 100 cells examined independent exper-
  HC510            HC334 pgsA444 zed-3069::Tn10            39, 50, 51;   iments. P values calculated using Studentâ€™s t test.
                                                              study               Bligh Dyer lipid extraction. Lipids extracted using acidic
  HC530            HC509 cdsA7 dgt::Tn10                   study         Bligh Dyer method previously described (23, 24). milli-
  HC571            NR754 âŒ¬clsA::kan                        34; study     liter cultures grown OD600 1.5, cells   HC575            NR754 pgsA444 zed-3069::Tn10            39, 50, 51;   harvested centrifugation. Cell pellets washed phos-
                                                              study           phate-buffered saline (PBS) resuspended 1 ml 0.1 N HCl.
  HC630            HC509 pgsA444 zed-3069::Tn10            39, 50, 51;   Methanol (2.5 ml) chloroform (1.25 ml) added form single-
                                                              study           phase solution (chloroform-methanol-0.1 N HCl [1:2:0.8 {vol/vol/vol}])
  HC960            HC334 cdsA9 dgt::Tn10                   study         incubated 30 min room temperature sporadic vortexing.
  HC961            HC509 cdsA9 dgt::Tn10                   study          0.1 N HCl (1.25 ml) chloroform (1.25 ml) added form
  HC962            NR754 cdsA9 dgt::Tn10                   study         phase solution (chloroform-methanol-0.1 N HCl [2:2:1.8 {vol/vol/
  HC1045           NR754 pASKA::plsC                       35; study     vol}]). solutions centrifuged 3,000 â«» g 25 min   HC1198           JAS193 cdsA7 dgt::Tn10                  study         room temperature. lower phase recovered dried nitro-
  HC1199           JAS193 cdsA9 dgt::Tn10                  study         gen stream.
  HC1240           HC342 pASKA::cdsA                       35; study         Mass spectrometry. Samples reconstituted 500 â?®l 1:1:0.3
  HC1241           HC962 pASKA::cdsA                       35; study     methanol-chloroform-water. Mass spectrometric analyses 
  JAS193           MC4100 âŒ¬bamE::kan                       J. Schwalm,        formed 6550 Accurate-Mass quadrupole time flight (Q-TOF) mass
                                                              unpublished     spectrometer (Agilent Technologies, , Santa Clara, CA), equipped
                                                              data            electrospray ionization (ESI) source operated negative-
Plasmids                                                                      positive-ion mode. Liquid chromatography (LC) performed 
  pET2342::lptD    lptD cloned pET2342                48                 ing 1290 Infinity HPLC (Agilent Technologies, , Santa Clara,
  pASKA::cdsA      IPTG inducible, Camr                    35                 CA) coupled mass spectrometer, scans m 200 1,000
  pASKA::plsC      IPTG inducible, Camr                    35                 2-GHz extended dynamic range. Nitrogen used drying gas, neb-
                                                                              ulizer gas, collision gas. Mass spectrometer operation conditions                                                                               follows: capillary voltage, 4,000 V; fragmentor voltage, 225 V; nebulizer
                                                                              gas, 35 lb/in2; drying gas, 13 liter/min; gas temperature, 275Â°C. 
MATERIALS METHODS                                                         strument control, data acquisition, data analysis performed Bacterial strains, plasmids, media, chemicals. strains used    Agilent Mass Hunter software (Agilent Technologies; version
work isogenic derivatives NR754, araDâ«¹ revertant MC4100          B.05.00), controlled chromatography 
(17, 18). Strains constructed generalized P1 transduction trans-       LC parameters follows: column, Agilent Poroshell-120
formation (19). Suppressor mutations mapped using pools ran-          EC-C18 (2.7 â?®m, 2.1 150 mm); autosampler temperature, 5Â°C; injec-
dom Tn10 insertions described previously (20). necessary, kan cas-      tion volume, 10 â?®l; column temperature, 60Â°C; solvent flow rate, 150
settes excised using Flp recombinase (21). Strains plasmids      â?®l/min. Solvent 1 mM ammonium acetate plus 0.2  acetic acid used work listed Table 1. cultures grown Luria-    90:10 water-methanol, solvent B 1 mM ammonium acetate plus
Bertani (LB) broth agar 37Â°C. mass spectrometry (MS), high-         0.2  acetic acid 2:98 methanolâ€“2-propanol. gradient 0 min,
pressure liquid chromatography (HPLC)-grade solvents (water, metha-           25  B; 2 min, 25  B; 4 min, 65  B; 16 min, 100  B; 20 min, 100  B; 21
nol, isopropanol), acetic acid, ammonium acetate obtained        min, 25  B; 22 min, 25  B. Postrun time 6 min. Fisher Scientific (Pittsburgh, PA).
    Antibiotic sensitivity assays. Efficiency plating assays (EOPs)     RESULTS
disk diffusion assays used determine antibiotic sensitivity.                                                                               Vancomycin-resistant suppressors lptD mutations map EOPs, strains grown overnight, serially diluted, replica
plated LB agar LB agar supplemented vancomycin (70 mg/liter,       cdsA. Escherichia coli lpt mutants exhibit defects transport
120 mg/liter, 140 mg/liter, 150 mg/liter, 200 mg/liter), 625 mg/liter      assembly LPS exhibit sensitivity detergents bacitracin, 1 mg/liter gentamicin, 10 mg/liter rifampin. disk diffu-   antibiotics (18, 25â€“31). lptDI54E, lptDV52E-I54E, lptDâŒ¬D57âŒ¬K60
sion assays, disks contained following amounts antibiotics: 1.25   harbor denoted mutations alter soluble N terminus mg ampicillin, 320 â?®g cetyltrimethylammonium bromide, 125 â?®g eryth-           OM beta-barrel protein LptD confer sensitivity vanco-


September 2014 Volume 196 Number 18                                                                                                       jb.asm.org 3215
Sutterlin et al.



                                                                                        cdsA essential gene (16, 34), suppressors 
                                                                                    null mutations. used complementation analysis 
                                                                                    termine cdsA7 cdsA9 mutations dominant
                                                                                    recessive. cdsA clone  Complete Set E. coli
                                                                                    K-12 ORF Archiveâ€? (ASKA) collection introduced                                                                                     cdsA7 cdsA9 backgrounds (35). Basal-level (uninduced) ex-
                                                                                    pression wild-type copy cdsA ASKA plasmid 
                                                                                    creased vancomycin resistance wild-type levels  Fig. S1
                                                                                    supplemental material). cdsA7 cdsA9 reces-
                                                                                    sive, conclude partial loss function mutations.
                                                                                        cdsA mutations alter cell size. Previously,                                                                                     shown mutations confer LPS transport defects                                                                                     suppressed mutations alter fatty acid biosynthesis (36),
                                                                                    wanted determine suppressors acted similar
                                                                                    manner. fabH accD mutations suppress certain lpt muta-
                                                                                    tions reducing cell size growth rate, turn decrease
                                                                                    rate growth cell envelope (36). cdsA7 cdsA9
                                                                                    mutants did exhibit decrease cell volume  Fig. S2                                                                                     supplemental material), growth rates did differ sig-
                                                                                    nificantly wild type  Table S1). conclude
                                                                                    results cdsA mutations suppress lptD
                                                                                    mutations decreasing rate growth cell envelope.
                                                                                        Partial loss function cdsA mutants generally increase
                                                                                    vancomycin resistance E. coli strains. cdsA sup-
                                                                                    pressors isolated different lptD mutant backgrounds,                                                                                     asked mode suppression specific lptD
                                                                                    mutant. simplicity, chose analyze cdsA mu-
                                                                                    tants (cdsA7 cdsA9) lptD mutant backgrounds
                                                                                    (lptDI54E lptDâŒ¬D57âŒ¬K60). cdsA7 cdsA9 able                                                                                     cross-suppress lptDI54E lptDâŒ¬D57âŒ¬K60, regardless lptD
                                                                                    background isolated (Fig. 2). demonstrates                                                                                     cdsA suppressors allele specific increase
                                                                                    vancomycin resistance generalized manner.
                                                                                        Mutants beta-barrel assembly machinery (Bam) increase
FIG 1 Vancomycin-resistant lptD suppressors map cdsA, gene respon-
sible conversion phosphatidic acid CDP-diacylglycerol.          sensitivity vancomycin impaired assembly OM pro-
inner membrane CdsA protein predicted seven transmembrane                teins (37, 38). âŒ¬bamE::kan allele null mutation 
domains (33). Vancomycin-resistant cdsA suppressors mapped mainly            moves BamE, lipoproteins Bam complex. Strains domains. Mutations V16G, L33P, âŒ¬56 â€“ 62, Y156D, L236Q                carrying âŒ¬bamE::kan allele exhibit mild OM protein assembly
isolated lptDV52E-I54E background. I203S isolated lptDI54E 
                                                                                    defects display increased sensitivity vancomycin (37).
ground, R263L isolated lptDâŒ¬D57âŒ¬K60 background. muta-
tions enclosed circles, I203S (cdsA7) R263L (cdsA9), characterized       cdsA7 cdsA9 introduced âŒ¬bamE::kan strain, study. (B) Biosynthetic pathway major phospholipids          vancomycin resistance increased (Fig. 3A). suggests Escherichia coli. Protein names boxes, arrow   cdsA7 cdsA9 increase vancomycin resistance general man-
signifies step act.                                               ner strain compromised OM.
                                                                                        test cdsA7 cdsA9 increase resistance vanco-
                                                                                    mycin wild-type strains, evaluated mutants oth-
mycin differing degrees. Spontaneously arising vancomycin-                       erwise wild-type background. LB plates supplemented resistant suppressors isolated LB medium supplemented                       200 mg/liter vancomycin, cdsA7 cdsA9 mutants able 120 mg/liter vancomycin.                                                       survive better wild type (Fig. 3B). suggests     strains carrying mutations, survivors arose                  cdsA7 cdsA9 strains altered way protects cell frequency 10â«º8, suppressors analyzed mapped                   vancomycin. Previously isolated cdsA mutants showed 
essential gene, cdsA. CdsA inner membrane protein respon-                     creased resistance erythromycin strain background
sible conversion PA CDP-diacylglycerol GPL bio-                    tested, effect mutations sensitivity synthesis (6, 15, 32). Figure 1A shows location different                antibiotics reported (16). Using disk diffusion assays,
cdsA mutations predicted CdsA structure (33). muta-                       checked cdsA mutants battery tions map transmembrane helices, affect                         antibiotics. slight increase resistance eryth-
protein stability membrane. Amino acid changes I203S                         romycin drug tested (norfloxacin, para-
(cdsA7) R263L (cdsA9) chosen representative exam-                       quat, cetyltrimethylammonium bromide, bacitracin, poly-
ples study located different parts              myxin B). Strikingly,  cdsA mutations
protein, unlike cdsA suppressors isolated,                    cause clear increase sensitivity ampicillin, moxalactam, genta- exhibit growth defects.                                             micin, rifampin.


3216    jb.asm.org                                                                                                                     Journal Bacteriology
                                                                                                               Phosphatidic Acid Increases Vancomycin Resistance




FIG 2 Partial loss function cdsA mutants pgsA444 suppress vancomycin sensitivity lptD mutants.   Efficiency plating assay (EOP) LB agar
plates supplemented 70 mg/liter, 140 mg/liter, 150 mg/liter vancomycin grown 37Â°C overnight. Suppression shown lptDI54E. Note chromosomal lptD allele âŒ¬lptD, lptD allele listed EOP present pET2342::lptD, leaky T7 promoter. T7 RNA polymerase present strains. (B) EOPs described panel  Suppression shown lptDâŒ¬D57âŒ¬K60.



   Changes phospholipid content confer vancomycin resis-                      shown accumulate PA (15, 16). expect tance. enzymes intermediates involved GPL biosyn-                     concomitant decrease CDP-diacylglycerol levels cdsA mu-
thesis identified lab Eugene Kennedy (Fig. 1B).                   tants, result decrease acidic GPL biosynthesis,
Strains harboring partial loss function mutations cdsA                CDP-diacylglycerol higher affinity PssA                                                                                  PgsA (15, 16).
                                                                                     hypothesized change phospholipid content                                                                                  OM result increased resistance vancomycin,
                                                                                 wondered accumulation PA                                                                                  decrease acidic GPLs. distinguish                                                                                  possibilities, introduced pgsA444, partially inactivating mu-
                                                                                 tation phosphatidylglycerophosphate synthetase (39),                                                                                  âŒ¬clsA::kan Keio collection (34) lptD
                                                                                 mutant strains (note unable construct                                                                                  lptDâŒ¬D57âŒ¬K60 âŒ¬clsA::kan double mutant, data                                                                                  shown). ClsA responsible significant portion CL pro-
                                                                                 duced cell, cls mutants shown lower
                                                                                 levels CL (24, 40). pgsA444 partially suppresses
                                                                                 vancomycin sensitivity lptD mutants, âŒ¬clsA::kan
                                                                                 does (Fig. 2). suggests increase negatively
                                                                                 charged PA species membrane decrease acidic
                                                                                 GPLs responsible increase vancomycin resistance.                                                                                  likely pgsA444 partially suppresses vancomycin
                                                                                 sensitivity lptD mutants does accumulate                                                                                  PA cdsA mutants. discovered pgsA444
                                                                                 confers increased vancomycin resistance wild-
                                                                                 type background (Fig. 3B). âŒ¬clsA::kan allele does confer
                                                                                 increased resistance fact renders cells sensitive                                                                                  vancomycin.
                                                                                     cdsA mutants accumulate PA. confirm genetic results,
FIG 3 cdsA mutants, pgsA444, plsC overexpression increase resistance      investigated GPL content strains harboring cdsA7, cdsA9,
vancomycin.   Partial loss function cdsA mutants suppress vancomy-      pgsA444 mutations. GPLs extracted cells
cin sensitivity cell envelope mutants. EOPs strains supplemented     using acidic Bligh Dyer method (23, 24). Lipids sep- 120 mg/liter vancomycin. (B) Partial loss function cdsA mutants      arated quantified Agilent quadrupole time flight (Q-
pgsA444 increase vancomycin resistance wild-type cells. EOPs strains
supplemented 200 mg/liter vancomycin. (C) Overproduction PlsC
                                                                                 TOF) liquid chromatography-mass spectrometry (LC-MS). Dis-
increases vancomycin resistance wild-type cells. EOPs strains supple-      tinct PA species summed, sum normalized mented 200 mg/liter vancomycin 0.1 mM IPTG.                             total PS content strain. PS levels did change signifi-


September 2014 Volume 196 Number 18                                                                                                            jb.asm.org 3217
Sutterlin et al.




FIG 4 PA accumulates cdsA mutants pgsA444 plsC overexpressed. PA quantified Q-TOF LC-MS. average fold differences PA species â«¾ standard errors experiments shown  . changes PA/PS reported â«¾ standard errors experiments  .
(B) CL levels decrease cdsA mutants pgsA444. CL quantified Q-TOF LC-MS. average fold differences CL species â«¾ standard errors experiments shown  . changes CL/PS reported â«¾ standard errors experiments  .




cantly strains tested. PA accumulates cdsA7,           DISCUSSION
cdsA9, pgsA444 strains (Fig. 4A). hypothesize                  OM permeability defects associated lptD
cdsA9 mutation compromises CdsA function severely                    mutants suppressed partial loss function mutations does cdsA7 PA levels higher cdsA9 mutant.              essential gene, cdsA. results selection increased correlates suppression seen lptD mutants                vancomycin resistance striking: suppression rare (Fig. 2); higher vancomycin concentrations, cdsA9 suppresses                seven suppressors analyzed altered seven different codons single
vancomycin sensitivity better does cdsA7, suggesting                 essential gene. cdsA mutations increase vancomycin resistance
greater PA accumulation results better suppression.                     lptD mutants, bam mutants, wild-type
pgsA444 mutant accumulates PA cdsA7                                                                                strain.  markedly increase resistance cdsA9 mutant does, correlates fact pgsA444
                                                                               antibiotic tested.  suppressors gene path-
does suppress vancomycin sensitivity (Fig. 2).                                                                                way specific;  drug specific. Using classic genetic meth-
cdsA7, cdsA9, pgsA444 mutants decreased CL levels
                                                                               ods Q-TOF LC-MS, increasing PA different
compared wild type (Fig. 4B), likely PA accumulating expense CL.                                             ways (using cdsA suppressors, pgsA444 mutation, overex-
   Overexpression plsC increases PA increases vancomy-                  pression plsC) increases vancomycin resistance E. coli. 
cin resistance. shown loss function mutations               clude vancomycin resistance increases consequence PA phospholipid biosynthesis pathway cause accumulation                  accumulation. PA increase vancomycin resistance. wondered                          difficult speculate accumulation PA results overproduction protein directly upstream PA synthesis,               increased vancomycin resistance primarily PlsC, cause accumulation PA,                    know vancomycin enters periplasm bind target,
increase vancomycin resistance. used plsC ASKA clone                 lipid II (13, 14). lpt compromised, LPS trans-
overexpress plsC wild-type background (35).                    port assembly slow, allowing PLs flip outer plsC expression induced 0.1 mM IPTG, increase                  leaflet OM (20). PLs self-associate form rafts PL vancomycin resistance observed (Fig. 3C). Q-TOF LC-MS                    bilayer OM allow diffusion hydrophobic mole-
confirms level induction plsC expression results            cules periplasm (41). obvious large, hydro- accumulation PA (Fig. 4A). results confirm accu-              philic molecule like vancomycin able cross mem-
mulation PA increases vancomycin resistance E. coli.                     brane way. Instead, possible vancomycin enters 

3218    jb.asm.org                                                                                                                   Journal Bacteriology
                                                                                                       Phosphatidic Acid Increases Vancomycin Resistance



cell â€œcracksâ€? bilayer disordered LPS-PL junctions       vated (9). Accumulation PA way OM
(41). predicts lpt mutant vancomycin           modified increase resistance antibiotics.
sensitive increase LPS-PL junctions, e., â€œcracksâ€?          emergence multidrug-resistant bacteria  life- membrane.                                                             threatening problem (47). Owing barrier properties     Ganong et al. shown cdsA mutants accumulate PA           OM, problem especially acute Gram-negative patho- IM OM (15). true roughly       gens. antibiotics work infections caused times PA IM OM, PA concentrations           Gram-positive bacteria fail used Gram-negative bac- OM 10-fold higher cdsA mutant          teria effectiveness OM barrier, wild type (15). vancomycin needs traverse          know modify agents reach OM act target periplasm, unlikely      targets. better understanding permeability properties PA accumulation IM contributing vancomycin resis-            OM modified help facilitate tance.  suggest PA accumulation OM im-              design new antibacterials.
pedes efficient entry vancomycin periplasm reduc-
ing size altering properties â€œcracks.â€? PA         ACKNOWLEDGMENTS
accumulation increases vancomycin resistance             material based work supported National Science
wise wild-type cell  propose presence small      Foundation Graduate Research Fellowship Program grant  PLs outer leaflet produce â€œcracksâ€? OM        DGE1148900 (H S.). work supported National
                                                                          Institute General Medical Sciences grant GM34821 (T.J.S.) NIH/ wild-type strains.
                                                                          NIGMS grant P50 GM071508 (S ).
    possible accumulation PA OM reduces              opinions, findings, conclusions recommendations ex- size â€œcracksâ€? increasing LPS assembly, increasing        pressed material author(s) necessarily
activity Lpt  decreasing PLs         reflect views National Science Foundation. outer leaflet increasing activity PldA Mla trans-        thank Silhavy lab, present past, helpful discussion port (20).  PA really intermediate PL       comments. thank Mark Rose Zemer Gitai helpful discus-
biosynthesis, present normally low levels,          sion critical analysis. grateful Thomas Bartlett help think unlikely.                                              imaging cell size analysis Jaclyn Schwalm strains.
    propose accumulation PA increases vancomycin
                                                                          REFERENCES
resistance altering biophysical properties OM. PA
                                                                           1. Silhavy TJ, Kahne D, Walker S. 2010. bacterial cell envelope. Cold
lacks head group increases membrane curvature,
                                                                              Spring Harb. Perspect. Biol. 2:a000414. http://dx.doi.org/10.1101 affect size properties â€œcracksâ€? (42, 43).        /cshperspect.a000414. addition increased membrane curvature, PA increases              2. Nikaido H. 2003. Molecular basis bacterial outer membrane permea-
negative charge OM, increase vancomycin                   bility revisited. Microbiol. Mol. Biol. Rev. 67:593â€“ 656. http://dx.doi.org
association OM (43). counterintui-               /10.1128/MMBR.67.4.593-656.2003.
                                                                           3. Bos MP, Robert V, Tommassen J. 2007. Biogenesis gram-negative
tive, studies shown CL microdomains interact                  bacterial outer membrane. Annu. Rev. Microbiol. 61:191â€“214. http://dx CAMPs prevent interacting targets,              .doi.org/10.1146/annurev.micro.61.080706.093245. increasing resistance (44, 45).                                    4. Raetz CR, Whitfield C. 2002. Lipopolysaccharide endotoxins. Annu. Rev.
    Changes GPL composition previously shown                  Biochem. 71:635â€“700. http://dx.doi.org/10.1146/annurev.biochem.71
                                                                              .110601.135414.
alter resistance susceptibility CAMPs antibiotics (9,           5. Ruiz N, Kahne D, Silhavy TJ. 2009. Transport lipopolysaccharide
46). Staphylococcus aureus, fmtC lysC mutations,                 cell envelope: long road discovery. Nat. Rev. Microbiol.
reduce lysyl-PG, increase resistance moenomycin vanco-                 7:677â€“ 683. http://dx.doi.org/10.1038/nrmicro2184.
mycin (46). increased net negative charge mutant              6. Dowhan W. 2013. retrospective: use Escherichia coli vehicle                                                                               study phospholipid synthesis function. Biochim. Biophys. Acta 1831:
membranes increase interaction drugs prevent               471â€“ 494. http://dx.doi.org/10.1016/j.bbalip.2012.08.007. interacting targets. Salmonella Typhimu-           7. Zhang YM, Rock  2008. Membrane lipid homeostasis bacteria.
rium, PhoPQ responds acidic pH CAMPs                     Nat. Rev. Microbiol. 6:222â€“233. http://dx.doi.org/10.1038/nrmicro1839.
increasing levels cardiolipin palmitoylated acyl-PG (9).            8. Wiesner J, Vilcinskas  2010. Antimicrobial peptides: ancient arm                                                                               human immune  Virulence 1:440 â€“ 464. http://dx.doi.org/10 increase GPLs correlates increase resis-             .4161/viru.1.5.12983.
tance CAMPs helps evade host immune (9).                9. Dalebroux ZD, Matamouros S, Whittington D, Bishop  Miller SI. speculation resistance increased             2014. PhoPQ regulates acidic glycerophospholipid content Salmo-
membrane curvature CAMP association CL mi-                    nella Typhimurium outer membrane. Proc. Natl. Acad. Sci. U. S.  111:
                                                                              1963â€“1968. http://dx.doi.org/10.1073/pnas.1316901111.
crodomains, occluding CAMP interactions tar-           10. Needham BD, Trent MS. 2013. Fortifying barrier: impact lipid
gets (9, 44, 45).                                                             remodelling bacterial pathogenesis. Nat. Rev. Microbiol. 11:467â€“
    mode resistance shown inherently different            481. http://dx.doi.org/10.1038/nrmicro3047. regulated PhoPQ  turned         11. Murata T, Tseng W, Guina T, Miller SI, Nikaido H. 2007. PhoPQ-
                                                                              mediated regulation produces robust permeability barrier palmitoylation PG increases, results reduction polar-        outer membrane Salmonella enterica serovar Typhimurium. J. Bacte-
ity increase hydrophobicity saturation mem-          riol. 189:7213â€“7222. http://dx.doi.org/10.1128/JB.00973-07.
brane (9, 10). work, overall increase PA, regard-   12. Cronan JE. 2003. Bacterial membrane lipids: stand? Annu. chain length saturation state  Fig. S3              Rev. Microbiol. 57:203â€“224. http://dx.doi.org/10.1146/annurev.micro.57
                                                                              .030502.090851.
supplemental material). result accumulation PA,    13. Pootoolal J, Neu J, Wright GD. 2002. Glycopeptide antibiotic resistance. reduction CL levels. contrasts increase       Annu. Rev. Pharmacol. Toxicol. 42:381â€“ 408. http://dx.doi.org/10.1146
CL levels observed Salmonella PhoPQ acti-               /annurev.pharmtox.42.091601.142813.



September 2014 Volume 196 Number 18                                                                                                     jb.asm.org 3219
Sutterlin et al.



14. Barna JC, Williams DH. 1984. structure mode action                    coli K-12 frame, single-gene knockout mutants: Keio collection.
    glycopeptide antibiotics vancomycin group. Annu. Rev. Microbiol.             Mol. Syst. Biol. 2:2006.0008. http://dx.doi.org/10.1038/msb4100050.
    38:339 â€“357. http://dx.doi.org/10.1146/annurev.mi.38.100184.002011.           35.   Kitagawa M, Ara T, Arifuzzaman M, Ioka-Nakamichi T, Inamoto E,
15. Ganong BR, Leonard JM, Raetz CR. 1980. Phosphatidic acid accumula-                  Toyonaga H, Mori H. 2005. Complete set ORF clones Escherichia
    tion membranes Escherichia coli mutants defective CDP-                 coli ASKA library  complete set E. coli K-12 ORF archive): unique
    diglyceride synthetase. J. Biol. Chem. 255:1623â€“1629.                               resources biological research. DNA Res. 12:291â€“299. http://dx.doi.org
16. Ganong BR, Raetz CR. 1982. Massive accumulation phosphatidic acid                /10.1093/dnares/dsi012.
    conditionally lethal CDP-diglyceride synthetase mutants cytidine       36.   Yao  Davis RM, Kishony R, Kahne D, Ruiz N. 2012. Regulation cell
    auxotrophs Escherichia coli. J. Biol. Chem. 257:389 â€“394.                        size response nutrient availability fatty acid biosynthesis Esch-
17. Casadaban MJ. 1976. Transposition fusion lac genes selected           erichia coli. Proc. Natl. Acad. Sci. U. S.  109:E2561â€“E2568. http://dx.doi
    promoters Escherichia coli using bacteriophage lambda Mu. J. Mol.            .org/10.1073/pnas.1209742109.
    Biol. 104:541â€“555. http://dx.doi.org/10.1016/0022-2836(76)90119-4.            37.   Rigel NW, Schwalm J, Ricci DP, Silhavy TJ. 2012. BamE modulates 18. Ruiz N, Gronenberg LS, Kahne D, Silhavy TJ. 2008. Identification             Escherichia coli beta-barrel assembly machine component BamA. J. Bacte-
    inner-membrane proteins required transport lipopolysaccha-               riol. 194:1002â€“1008. http://dx.doi.org/10.1128/JB.06426-11.
    ride outer membrane Escherichia coli. Proc. Natl. Acad. Sci.        38.   Ricci DP, Hagan CL, Kahne D, Silhavy TJ. 2012. Activation     U. S.  105:5537â€“5542. http://dx.doi.org/10.1073/pnas.0801196105.                  Escherichia coli beta-barrel assembly machine (Bam) required essen-
19. Silhavy TJ, Berman ML, Enquist LW. 1984. Experiments gene                      tial components interact properly substrate. Proc. Natl. Acad. Sci.
    fusions. Cold Spring Harbor Laboratory Press, Plainview, NY.                        U. S.  109:3487â€“3491. http://dx.doi.org/10.1073/pnas.1201362109.
20. Malinverni JC, Silhavy TJ. 2009. ABC transport maintains       39.   Nishijima M, Raetz CR. 1979. Membrane lipid biogenesis Escherichia
    lipid asymmetry gram-negative outer membrane. Proc. Natl. Acad.              coli: identification genetic loci phosphatidylglycerophosphate syn-
    Sci. U. S.  106:8009 â€“ 8014. http://dx.doi.org/10.1073/pnas.0903229106.           thetase construction mutants lacking phosphatidylglycerol. J. Biol.
21. Cherepanov PP, Wackernagel W. 1995. Gene disruption Escherichia                  Chem. 254:7837â€“7844.
    coli: TcR KmR cassettes option Flp-catalyzed excision      40.   Shibuya  Miyazaki C, Ohta  1985. Alteration phospholipid com-
    antibiotic-resistance determinant. Gene 158:9 â€“14. http://dx.doi.org            position combined defects phosphatidylserine cardiolipin syn-
    /10.1016/0378-1119(95)00193                                                       thases physiological consequences Escherichia coli. J. Bacteriol. 161:
22. Sliusarenko O, Heinritz J, Emonet T, Jacobs-Wagner C. 2011. High-                   1086 â€“1092.
    throughput, subpixel precision analysis bacterial morphogenesis        41.   Nikaido H. 2005. Restoring permeability barrier function outer mem-
    intracellular spatio-temporal dynamics. Mol. Microbiol. 80:612â€“ 627.                brane. Chem. Biol. 12:507â€“509. http://dx.doi.org/10.1016/j.chembiol
    http://dx.doi.org/10.1111/j.1365-2958.2011.07579.x.                                 .2005.05.001.
23. Bligh  Dyer WJ. 1959. rapid method total lipid extraction         42.   McMahon HT, Gallop JL. 2005. Membrane curvature mechanisms
                                                                                        dynamic cell membrane remodelling. Nature 438:590 â€“596. http://dx
    purification.  J. Physiol. Pharmacol. 37:911â€“917. http://dx.doi.org/10
                                                                                        .doi.org/10.1038/nature04396.
    .1139/y59-099.
                                                                                  43.   Kooijman EE, Burger KN. 2009. Biophysics function phosphatidic
24. Tan BK, Bogdanov M, Zhao J, Dowhan W, Raetz CR, Guan  2012.
                                                                                        acid: molecular perspective. Biochim. Biophys. Acta 1791:881â€“ 888. http:
    Discovery cardiolipin synthase utilizing phosphatidylethanolamine
                                                                                        //dx.doi.org/10.1016/j.bbalip.2009.04.001.
    phosphatidylglycerol substrates. Proc. Natl. Acad. Sci. U. S. 
                                                                                  44.   Tran TT, Panesso D, Mishra NN, Mileykovskaya E, Guan  Munita
    109:16504 â€“16509. http://dx.doi.org/10.1073/pnas.1212797109.
                                                                                        JM, Reyes J, Diaz L, Weinstock GM, Murray  Shamoo Y, Dowhan
25. Grabowicz M, Yeh J, Silhavy TJ. 2013. Dominant negative lptE mutation
                                                                                        W, Bayer  Arias CA. 2013. Daptomycin-resistant Enterococcus faecalis
    supports role LptE plug LptD barrel. J. Bacteriol.           diverts antibiotic molecule division septum remodels cell
    195:1327â€“1334. http://dx.doi.org/10.1128/JB.02142-12.                               membrane phospholipids. mBio 4(4):e00281â€“13. http://dx.doi.org/10
26. Freinkman E, Chng SS, Kahne D. 2011. complex inserts lipo-                 .1128/mBio.00281-13.
    polysaccharide bacterial outer membrane forms protein          45.   Hartmann M, Berditsch M, Hawecker J, Ardakani MF, Gerthsen D,
    plug barrel. Proc. Natl. Acad. Sci. U. S.  108:2486 â€“2491. http://dx          Ulrich  2010. Damage bacterial cell envelope antimicrobial
    .doi.org/10.1073/pnas.1015617108.                                                   peptides gramicidin S PGLa revealed transmission scanning
27. Freinkman E, Okuda S, Ruiz N, Kahne D. 2012. Regulated assembly                  electron microscopy. Antimicrob. Agents Chemother. 54:3132â€“3142.
    transenvelope protein complex required lipopolysaccharide ex-               http://dx.doi.org/10.1128/AAC.00124-10.
    port. Biochemistry 51:4800 â€“ 4806. http://dx.doi.org/10.1021/bi300592c.       46.   Nishi H, Komatsuzawa H, Fujiwara T, McCallum N, Sugai M. 2004.
28. Villa R, Martorana  Okuda S, Gourlay LJ, Nardini M, Sperandeo P,                 Reduced content lysyl-phosphatidylglycerol cytoplasmic mem-
    Deho G, Bolognesi M, Kahne D, Polissi  2013. Escherichia coli Lpt             brane affects susceptibility moenomycin, vancomycin, genta-
    transenvelope protein complex lipopolysaccharide export assembled            micin, antimicrobial peptides, Staphylococcus aureus. Antimicrob.
    conserved structurally homologous domains. J. Bacteriol. 195:1100 â€“             Agents Chemother. 48:4800 â€“ 4807. http://dx.doi.org/10.1128/AAC.48.12
    1108. http://dx.doi.org/10.1128/JB.02057-12.                                        .4800-4807.2004.
29. Sampson BA, Misra R, Benson SA. 1989. Identification character-           47.   Dortet L, Poirel L, Nordmann P. 2014. Worldwide dissemination     ization new gene Escherichia coli K-12 involved outer membrane           NDM-type carbapenemases gram-negative bacteria. Biomed. Res. Int.
    permeability. Genetics 122:491â€“501.                                                 2014:249856. http://dx.doi.org/10.1155/2014/249856.
30. Sperandeo P, Pozzi C, Deho G, Polissi  2006. Non-essential KDO              48.   Wu T, McCandlish AC, Gronenberg LS, Chng SS, Silhavy TJ, Kahne D.
    